Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9 USD | -1.85% | -7.69% | +17.19% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 494M 41.21B |
---|---|---|---|---|---|
Net income 2024 * | -79M -6.59B | Net income 2025 * | -101M -8.42B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.81
x | P/E ratio 2025 * |
-4.57
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.7% |
Latest transcript on Astria Therapeutics, Inc.
1 day | -1.85% | ||
1 week | -7.69% | ||
Current month | -36.06% | ||
1 month | -33.48% | ||
3 months | -16.28% | ||
6 months | +91.08% | ||
Current year | +17.19% |
Managers | Title | Age | Since |
---|---|---|---|
Jill Milne
FOU | Founder | 56 | 26/08/26 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 01/11/01 |
Chief Tech/Sci/R&D Officer | - | 15/22/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 01/14/01 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 04/19/04 |
Director/Board Member | 75 | 05/16/05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 9 | -1.85% | 1,133,619 |
25/24/25 | 9.17 | +1.89% | 1,324,385 |
24/24/24 | 9 | -6.64% | 659,022 |
23/24/23 | 9.64 | -1.63% | 748,168 |
22/24/22 | 9.8 | +0.51% | 1,527,907 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.19% | 494M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ATXS Stock